Formulation: A solid
Formal Name: L-tyrosylglycyl-L-arginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L-glutaminyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-threonyl-L-lysyl-L-serylglycyl-L-valyl-L-tyrosyl-L-leucyl-L-valylglycyl-L-arginyl-L-arginyl-L-arginyl-glycine
Purity: ≥95%
Formula Markup: C132H237N59O31 • XCF3COOH
Formula Weight: 3146,7
Shelf life (days): 1460
Notes: Tat-βsyn-degron is an α-synuclein knockdown peptide.{69410} It is composed of the HIV-1 Tat plasma membrane transduction domain, the α-synuclein binding domain βsyn which corresponds to amino acids 36-45 of β-synuclein, and the proteasomal targeting domain degron. Tat-βsyn-degron binds to recombinant α-synuclein in a peptide-protein binding assay and reduces α-synuclein levels in primary rat cortical neuron cultures, an effect that can be prevented by the proteasomal inhibitor MG132. In vivo, Tat-βsyn-degron (40 mg/kg) reduces brain α-synuclein levels in M38 transgenic mice that overexpress human A53T mutant α-synuclein. It also reduces phosphorylated α-synuclein levels in the substantia nigra and the pons, as well as neuroinflammation in a mouse model of spreading synucleinopathy induced by α-synuclein preformed fibrils. Tat-βsyn-degron (6 µmol/kg, i.p.) protects against dopaminergic neuron loss and rescues motor deficits in a mouse model of MPTP-induced Parkinson’s disease.